Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Common Equity (2016 - 2025)

Haemonetics has reported Common Equity over the past 16 years, most recently at $911.5 million for Q4 2025.

  • For Q4 2025, Common Equity rose 0.51% year-over-year to $911.5 million; the TTM value through Dec 2025 reached $911.5 million, up 0.51%, while the annual FY2025 figure was $820.8 million, 14.49% down from the prior year.
  • Common Equity for Q4 2025 was $911.5 million at Haemonetics, up from $849.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $960.0 million in Q1 2024 and troughed at $677.1 million in Q3 2021.
  • A 5-year average of $824.9 million and a median of $835.0 million in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: grew 24.62% in 2021 and later fell 14.49% in 2025.
  • Year by year, Common Equity stood at $698.5 million in 2021, then grew by 11.08% to $776.0 million in 2022, then grew by 21.57% to $943.3 million in 2023, then decreased by 3.86% to $906.9 million in 2024, then increased by 0.51% to $911.5 million in 2025.
  • Business Quant data shows Common Equity for HAE at $911.5 million in Q4 2025, $849.2 million in Q3 2025, and $882.3 million in Q2 2025.